Chicago / Edinburgh
IPOX® Schuster LLC
Home / IPO Calendar
USA · Nasdaq

ADARx Pharmaceuticals

ADARx Pharmaceuticals develops RNA-targeted medicines designed to selectively control disease-related targets.

ADARx Pharmaceuticals (Ticker: ADRX US) develops RNA-targeted treatments designed to selectively control disease-related targets, with candidates spanning several therapeutic areas. Its technologies are designed to selectively control the expression of disease-related targets. Its pipeline includes candidates for complement-mediated, genetic, cardiovascular, thrombosis, central nervous system and metabolic diseases, including obesity. A collaboration and license option agreement with AbbVie covers siRNA therapeutics across multiple disease areas, including neuroscience, immunology and oncology.

The scheduled listing date on Nasdaq was September 25, 2026. The proposed offering comprises 21,875,000 shares at an indicative price range of $15.00–17.00 per share. At the indicative range midpoint, the base offering would represent $350.00 million in gross proceeds, excluding any unexercised over-allotment.

J.P. Morgan, Morgan Stanley, TD Cowen and UBS are bookrunners.

Prepared with IPOX® AI assistance. Information may contain errors.

Reuters: IPOX® Research Associate Lukas Muehlbauer Comments on ADARx IPO Debut and Biotech Market Momentum (Updated)

Reuters · September 22, 2026

Reuters: IPOX® Research Associate Lukas Muehlbauer Comments on ADARx IPO Debut and Biotech Market Momentum (Updated)

Reuters reports that ADARx Pharmaceuticals raised $446.3 million in an upsized U.S. IPO, with shares opening 30% above the $17 offer price. IPOX® Associate Lukas Muehlbauer, who commented ahead of the offering on AbbVie’s backing and biotech investor selectivity, spoke with Reuters again after the company began trading. He highlighted AbbVie’s validation, ADARx’s Phase 3 lead drug and broader development platform, while noting that investors remain focused on mature clinical assets and key catalyst milestones across the biotech IPO market.

Read article : Reuters: IPOX® Research Associate Lukas Muehlbauer Comments on ADARx IPO Debut and Biotech Market Momentum (Updated)

Prepared with IPOX® AI assistance. Information may contain errors.

THE IPOX® NEWSLETTERS

Stay ahead of the next listing.

Research and insight from the global new listings market.

Explore our newsletters